Clinical Trials Directory

Trials / Completed

CompletedNCT03240575

The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus

A Randomized, Double-blind, Double-dummy, Active-controlled, Multi-center, Parallel Group Study to Show the Superiority in Lung Function of 12 Weeks Once Daily Treatment With Orally Inhaled Tiotropium+Olodaterol Fixed Dose Combination Delivered by the Respimat® Inhaler vs. 12 Weeks Twice Daily Treatment With Fluticasone Propionate+Salmeterol Fixed Dose Combination Delivered by the Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD) [ENERGITO® 2]

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
302 (actual)
Sponsor
Boehringer Ingelheim · Industry
Sex
All
Age
40 Years
Healthy volunteers
Not accepted

Summary

The primary objective of the trial is to show superiority in lung function of once daily (2 inhalations) treatment with orally inhaled tiotropium+olodaterol fixed dose combination to twice daily (one inhalation) treatment with fluticasone propionate+salmeterol fixed dose combination over 12 weeks in patients with Chronic Obstructive Pulmonary Disease (COPD). A Digital Health (DH) exploratory study has been integrated into the main study as a site specific study. The DH exploratory study will be performed at a single site; the site is also participating in the main study. The DH exploratory study site will enter (randomize) approximately 20 patients (subjects) (in addition to the patients to be enrolled in the main study at this site). The patients enrolled in the DH exploratory study are not considered to be part of the main study (i.e. data collected in the DH exploratory study will be analyzed separately from the data collected in the main study).

Conditions

Interventions

TypeNameDescription
DRUGTiotropiumFixed Dose Combination
DRUGOlodaterolFixed Dose Combination
DRUGFluticasone propionateFixed Dose Combination
DRUGSalmeterolFixed Dose Combination

Timeline

Start date
2017-08-14
Primary completion
2019-04-08
Completion
2019-05-06
First posted
2017-08-07
Last updated
2020-04-16
Results posted
2020-04-16

Locations

45 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT03240575. Inclusion in this directory is not an endorsement.